Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:48:50 EDT Wed 01 May 2024
Enter Symbol
or Name
USA
CA



Q:BCRX - BIOCRYST PHARMACEUTICALS INC - http://www.biocryst.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BCRX - Q0.14.18·4.710.24.57+0.4410.75,162.822,38117,1924.18  4.77  4.159.065  4.0319:17:55Apr 2215 min RT 2¢

Recent Trades - Last 10 of 17192
Time ETExPriceChangeVolume
19:17:55Q4.55010.42015
18:43:08Q4.52120.39125
18:38:33Q4.52170.39172
18:17:35Q4.58910.45915
18:17:02Q4.590.464,150
18:16:43Q4.57020.44024
17:40:21Q4.590.4622
17:39:48Q4.590.4636
17:36:58Q4.570.4411
17:19:53Q4.61170.4817300

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-22 07:01U:BCRXNews ReleaseBioCryst to Report First Quarter 2024 Financial Results on May 6
2024-04-17 04:31U:BCRXNews ReleaseBioCryst Announces Approval of ORLADEYO(TM) (berotralstat) by the Brazilian Health Regulatory Agency
2024-04-03 07:00U:BCRXNews ReleaseBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-25 16:01U:BCRXNews ReleaseBioCryst to Present at Upcoming Investor Conferences
2024-03-05 07:02U:BCRXNews ReleaseBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-26 07:00U:BCRXNews ReleaseBioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones
2024-02-23 07:00U:BCRXNews ReleaseBioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO(TM) (berotralstat) Treatment
2024-02-21 16:02U:BCRXNews ReleaseBioCryst to Present at Upcoming Investor Conferences
2024-02-19 07:55U:BCRXNews ReleaseBioCryst Launches ORLADEYO ‚ ® (berotralstat) in Italy
2024-02-12 07:01U:BCRXNews ReleaseBioCryst to Report Fourth Quarter 2023 Financial Results on February 26
2024-02-05 07:00U:BCRXNews ReleaseBioCryst to Present New ORLADEYO ‚ ® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
2024-02-02 07:01U:BCRXNews ReleaseBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-05 16:01U:BCRXNews ReleaseBioCryst Announces Preliminary Full Year 2023 ORLADEYO ‚ ® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability
2024-01-03 16:02U:BCRXNews ReleaseBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-03 07:01U:BCRXNews ReleaseBioCryst to Present at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-19 07:00U:BCRXNews ReleaseBioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO ‚ ® (berotralstat)
2023-12-05 16:02U:BCRXNews ReleaseBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-29 07:00U:BCRXNews ReleaseBioCryst Announces Approval of ORLADEYO ‚ ® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina
2023-11-21 16:02U:BCRXNews ReleaseBioCryst to Present at Upcoming Investor Conferences
2023-11-21 07:00U:BCRXNews ReleaseBioCryst Launches ORLADEYO ‚ ® ‚  (berotralstat) in Spain